Huang Xinyan, Dale Elena, Brodbeck Robbin M, Doller Dario
Molecular Pharmacology & SAR. Neuroinflammation Disease Biology Unit, Lundbeck Research USA, 215 College Road, Paramus, NJ 07652, USA.
Curr Top Med Chem. 2014;14(15):1755-70. doi: 10.2174/1568026614666140902143830.
Drug design necessitates a clear understanding of the phenotypic response to be elicited by a given ligandtarget interaction. This relationship is relatively well understood for classical biological targets of drug action, but for some novel targets, notably those amenable to allosteric modulation, developing such understanding may represent a more challenging task. In order to gain knowledge on the nature of the functional response derived from mGlu4 receptor activation, its molecular and cell biology are reviewed, including signalling pathways involved, receptor localization in central nervous system and beyond, and potential genetic links to disease. Broadly held views for both, orthosteric agonists as well as allosteric modulators, are compared with specific observations for the case of mGlu4 receptor activation via orthosteric and allosteric mechanisms. First, sub-type selectivity and brain penetration of amino acid mGlu4 receptor agonists are discussed, followed by the quantification of functional allosteric effects, the potential role of heterodimers in the functional response, and the observation of supra-physiological efficacy of mGlu4 receptor PAMs. We show that, in our analysis, these attributes differ from those that may be expected by extrapolating from broad knowledge. In addition, recent progress with mGlu4 receptor radioligands and PET ligands is summarized.
药物设计需要清楚地了解给定配体-靶点相互作用所引发的表型反应。对于药物作用的经典生物学靶点,这种关系相对容易理解,但对于一些新型靶点,尤其是那些适合变构调节的靶点,形成这种理解可能是一项更具挑战性的任务。为了了解源自代谢型谷氨酸受体4(mGlu4)激活的功能反应的本质,本文综述了其分子生物学和细胞生物学,包括相关的信号通路、在中枢神经系统及其他部位的受体定位,以及与疾病潜在的遗传联系。本文将对正构激动剂和变构调节剂的普遍观点,与通过正构和变构机制激活mGlu4受体的具体观察结果进行比较。首先,讨论氨基酸mGlu4受体激动剂的亚型选择性和脑渗透性,随后对功能性变构效应进行量化,探讨异二聚体在功能反应中的潜在作用,以及观察mGlu4受体正变构调节剂的超生理效能。我们表明,在我们的分析中,这些特性与从广泛知识推断出的预期特性有所不同。此外,还总结了mGlu4受体放射性配体和正电子发射断层扫描(PET)配体的最新进展。